IP Library Granted Patent US 12661412
Granted Patent B2
US 12661412 · App. 18/490,841 · Granted Jun 23, 2026

Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system

Inventors: Miguel Sena Esteves (Worcester, MA); Ana Rita Batista (Worcester, MA); Sourav Roy Choudhury (Worcester, MA)
Assignee: University of Massachusetts
A61K48/0008A61K9/0085A61K31/351A61K31/4706A61K31/5415A61K31/7016A61K38/1709A61K47/42A61K47/62A61K47/6455C07K14/775C12N15/63C12N15/64C12N15/79C12N15/86C07K5/0808C07K2319/00C07K2319/33C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12661412
App. No.
18/490,841
Granted
Jun 23, 2026
Kind
B2
Abstract

The disclosure relates, in some aspects, to compositions and methods for enhanced delivery of a transgene to the central nervous system (CNS) of a subject. In some embodiments, the transgene is delivered by recombinant AAV (rAAV). In some embodiments, the method of enhancing transgene delivery comprises administering a blood brain barrier (BBB)-crossing molecule (e.g., K16ApoE) and an rAAV comprising a transgene to a subject.

Claims (8)

1 . A method for delivering a transgene to CNS tissue in a subject, the method comprising co-administering to the subject:

(i) an effective amount of a targeting composition, wherein the targeting composition comprises a hydrophilic peptide comprising the amino acid sequence of SEQ ID NO: 17; and,

(ii) an effective amount of a recombinant adeno-associated virus (rAAV) comprising a nucleic acid comprising a promoter operably linked to a transgene and a capsid protein comprising an N-terminally grafted heterologous targeting peptide comprises or consists of a sequence selected from the group consisting of SEQ ID NOS: 15-17; wherein the co-administering comprises systemic co-injection.

2 . The method of claim 1 , wherein the capsid protein has a serotype selected from the group consisting of AAV1, AAV2, AAV2i8, AAV2.5, AAV6, AAV8, AAVrh8, AAV9, AAVrh10, AAV-B1, AAV9.45A-String, AAV9.45Angiopep, AAV9.47-Angiopep, and AAV9.47-AS.

3 . The method of claim 1 , wherein the capsid protein comprises or consists of a sequence selected from the group consisting of SEQ ID NOS: 10-14.

4 . The method of claim 1 , wherein the N-terminally grafted heterologous targeting peptide is expressed on the surface of the rAAV.

5 . The method of claim 1 , wherein the capsid protein is a VP2 capsid protein.

6 . The method of claim 1 , wherein the transgene is a CNS-associated transgene selected from the group consisting of ALS2, ANG, ATXN2, C9orf72, DCTN1, FIG. 4 , FUS, NEFH, OPTN, PFN1, PRPH, SETX, SIGMAR1, SMN1, SOD1, SPG11, TARDBP, UBQLN2, VAPB, VCP, Htt, Xbpls, CRAG, MAN2B1, MAN2B2, MAN2C1, AGA, CLN1, CLN2, CLN3, CLN5, CLN6, MFSD8, CLN8, CTSD, MANBA, CTNS, LAMP2, GLA, ASAH1, FUCA1, CTSA, GBA, GALC, GLB1, HEXA, HEXB, ARSA, IDUA, IDS, SGSH, NAGLU, HGSNAT, GNS, GALNS, ARSB, GUSB, HYAL1, SMPD1, NPC1, NPC2, GAA, NAGA, SLCA17A5, and LAL.